These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2475628)

  • 1. Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine.
    Botros S; Lipkowski AW; Larson DL; Stark PA; Takemori AE; Portoghese PS
    J Med Chem; 1989 Sep; 32(9):2068-71. PubMed ID: 2475628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
    Fang X; Larson DL; Portoghese PS
    J Med Chem; 1997 Sep; 40(19):3064-70. PubMed ID: 9301669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphine analgesia after intrathecal administration of a narcotic agonist, chloroxymorphamine and antagonist, chlornaltrexamine.
    Larson AA; Armstrong MJ
    Eur J Pharmacol; 1980 Nov; 68(1):25-31. PubMed ID: 6161013
    [No Abstract]   [Full Text] [Related]  

  • 4. Opioid agonist and antagonist bivalent ligands as receptor probes.
    Portoghese PS; Ronsisvalle G; Larson DL; Yim CB; Sayre LM; Takemori AE
    Life Sci; 1982 Sep 20-27; 31(12-13):1283-6. PubMed ID: 6292615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity.
    Caruso TP; Takemori AE; Larson DL; Portoghese PS
    Science; 1979 Apr; 204(4390):316-8. PubMed ID: 86208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist-antagonist properties of fluorescent opioid probes in the guinea-pig myenteric plexus-longitudinal muscle preparation.
    Koman A; Einarsson M; Terenius L
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Dec; 331(4):355-8. PubMed ID: 2419770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 10-Ketonaltrexone and 10-ketooxymorphone.
    Archer S; Seyed-Mozaffari A; Ward S; Kosterlitz HW; Paterson SJ; McKnight AT; Corbett AD
    J Med Chem; 1985 Jul; 28(7):974-6. PubMed ID: 2409281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diastereoisomeric N-tetrahydrofurfurylnoroxymorphones with opioid agonist--antagonist properties.
    Merz H; Stockhaus K; Wick H
    J Med Chem; 1977 Jun; 20(6):844-6. PubMed ID: 69027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.
    Takemori AE; Larson DL; Portoghese PS
    Eur J Pharmacol; 1981 Apr; 70(4):445-51. PubMed ID: 6263637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid agonist and antagonist activities of morphindoles related to naltrindole.
    Portoghese PS; Larson DL; Sultana M; Takemori AE
    J Med Chem; 1992 Nov; 35(23):4325-9. PubMed ID: 1333013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting agonist and antagonist activities of naltrexamine bivalent ligands in mice.
    Takemori AE; Yim CB; Larson DL; Portoghese PS
    Eur J Pharmacol; 1990 Sep; 186(2-3):285-8. PubMed ID: 1963149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
    Ohkawa S; DiGiacomo B; Larson DL; Takemori AE; Portoghese PS
    J Med Chem; 1997 May; 40(11):1720-5. PubMed ID: 9171881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diastereomeric 6-desoxy-6-spiro-alpha-methylene-gamma-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted michael acceptor ligand.
    Koolpe GA; Nelson WL; Gioannini TL; Angel L; Simon EJ
    J Med Chem; 1984 Dec; 27(12):1718-23. PubMed ID: 6209395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of 7-arylmorphinans. Probing the "address" requirements for selectivity at opioid delta receptors.
    Gao P; Larson DL; Portoghese PS
    J Med Chem; 1998 Jul; 41(16):3091-8. PubMed ID: 9685249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid agonists and antagonists. 6-Desoxy-6-substituted lactone, epoxide, and glycidate ester derivatives of naltrexone and oxymorphone.
    Koolpe GA; Nelson WL; Gioannini TL; Angel L; Appelmans N; Simon EJ
    J Med Chem; 1985 Jul; 28(7):949-57. PubMed ID: 2409280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential irreversible ligands for opioid receptors. Cinnamoyl derivatives of beta-naltrexamine.
    Derrick I; Lewis JW; Moynihan HA; Broadbear J; Woods JH
    J Pharm Pharmacol; 1996 Feb; 48(2):192-6. PubMed ID: 8935170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine.
    Caruso TP; Larson DL; Portoghese PS; Takemori AE
    J Pharmacol Exp Ther; 1980 Jun; 213(3):539-44. PubMed ID: 6162947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.
    Williams DA; Zheng Y; David BG; Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Selley DE; Dewey WL; Akbarali HI; Zhang Y
    ACS Chem Neurosci; 2016 Aug; 7(8):1120-9. PubMed ID: 27269866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid bivalent ligands with opiate and enkephalin pharmacophores.
    Portoghese PS; Larson DL; Ronsisvalle G; Schiller PW; Nguyen TM; Lemieux C; Takemori AE
    J Med Chem; 1987 Nov; 30(11):1991-4. PubMed ID: 2444704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.